Innovations in The Management of Diabetes

Summary

Innovations in the Management of Diabetes

Next generation treatments and market dynamics

Business Intelligence for the Pharmaceutical Industry

Business Insights' portfolio of healthcare management reports is designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions.

The strength of our research and analysis is derived from access to unparalleled databases and libraries of information and the use of proprietary analytic techniques. Business Insights reports are authored by independent experts and contain findings garnered from dedicated primary research. Our authors' leading positions secure them access to interview key executives and to establish which issues will be of greatest strategic significance for the industry.

Our healthcare portfolio of reports can be used across a wide range of business functions to assess market conditions and devise future strategy. Our reports cover key areas including strategy, industry analysis, market outlook, new business opportunities and strategic insight.

Some key findings from this report

• The global diabetes market value was $24,275mn in 2007, having increased by 13.8% since 2006. The market has maintained steady growth in recent years, with a CAGR of 13.2% over 2003-07.
• OAD drugs and non-invasive insulin drug delivery technologies continue to offer significant potential for market expansion, despite several innovative introductions within new drug classes, such as GLP-1 agonists and DDP-IV inhibitors.
• A number of pharma companies are re-focusing on co-morbidities such as hypertension, dyslipidemia and obesity for innovative product development. Sanofi-Aventis' Acomplia (rimonabant) is a first-in-class CB-1 antagonist indicated for the treatment of overweight patients with associated Type 2 diabetes or dyslipidemia risk factors.
• Metabolic syndrome has become a focal area for drug developers. The syndrome refers to a clustering of CVD risk factors whose underlying pathophysiology is related to insulin resistance.
• The FDA is considering the implementation of stricter standards when testing diabetes drugs for related cardiovascular risks. The possibility of stricter controls in diabetes drugs development will be a difficult obstacle for several emerging agents.

Innovations in the Management of Diabetes

Diabetes has become the fifth leading cause of death across developed markets, and cases of the disease are forecast to grow by 7.1% across the globe by 2013. The market for innovative diabetes treatments will be driven by this projected rise in prevalence, together with the substantial unmet need for drugs that can effectively halt or reverse disease progression. Although extended lifecycle management for existing antidiabetic therapies may offer sales growth in the short term, the development of new drugs from novel classes will become increasingly important in the future. However, the potential introduction of stricter regulations for diabetes drug development and recent setbacks for novel products have increased speculation about the potential of innovative treatments.

Innovations in the Management of Diabetes:

Next generation treatments and market dynamics' is a new report published by Business Insights that analyzes the emerging drug classes, novel drug delivery technologies and future growth drivers of the diabetes market. This report explores the major trends and issues affecting the development of novel products and assesses the future potential of leading innovations. The major areas of unmet need in the market are identified and the currently marketed portfolios and developmental compounds of key companies operating within the sector are assessed. This report also examines recent concerns about the safety profiles of marketed products and the possible implementation of stricter FDA regulations.

Explore the latest trends and innovations in diabetes treatments, assess the currently marketed portfolios and pipelines of leading players and identify future market opportunities with this report...

Top five reasons to order your copy today

• Forecast sales growth for the global diabetes market to 2012 and assess the epidemiology and prevalence rates of Type 1/ Type 2 diabetes with this report's detailed analysis across Japan, France, Germany, Italy, Spain, the UK and the US.
• Examine the major unmet needs within the global diabetes market, identify the latest key events and understand the most important trends and issues affecting major companies operating in this sector.
• Discover which innovations and new compounds have the greatest potential to catalyze portfolio growth by gaining insights into future growth drivers, emerging drug classes and novel delivery technologies.
• Compare the currently marketed portfolios and product pipelines of key players in the diabetes market and understand how competitive dynamics will change with this report's assessment of companies including Novo Nordisk, Takeda, Sanofi-Aventis, GSK and Lilly.
• Evaluate the potential of leading competitive strategies with this report's examination of lifecycle management, diversification, franchise development and new market entry.

Key issues examined in this report...

• The diagnosis/treatment gap. With prevalence rates of diabetes continuing to increase globally, it is estimated that only 50% of Type 2 diabetes patients across the seven major markets have been diagnosed, with only 80% of these patients receiving treatment.
• Inhaled insulin failure. The market withdrawal of SanofiAventis/Pfizer's Exubera has been compounded by the suspension of NovoNordisk's AERx iDMS, following claims that the product lacks the potential to offer significant benefits over injected formulas. Lilly/Alkermes ceased development of AIR in March 2008 on the same grounds.
• New drug classes. The diabetes treatment paradigm may potentially be altered following the introduction of several new drugs that target the underlying causes of diabetes rather than the symptoms.
• Potential for innovatives. The global diabetes market is forecast to grow significantly over the next five years, driven by an increasing global prevalence creating expanded patient populations and the continued launch of novel drugs. Immense market potential exists for companies who address combined risk factors effectively.

Your questions answered...

• Which markets will experience an increase in the prevalence of diabetes?
• What are the latest technological developments in this field?
• Which treatment areas have become the focus of R&D investment?
• Are currently marketed innovatives satisfying demand?
• What are the drivers and resistors to growth for new products?
• Which pharma companies are implementing lifecycle management strategies for their diabetes portfolios?
• What are the implications of stricter FDA regulations for product approvals?
• How can companies most effectively prepare for impending changes to the market for innovative treatments?

Contents

• Innovations in the Management of Diabetes
• Executive Summary
• Introduction
• Currently marketed innovatives
• Future drivers of growth and innovation
• Key companies and pipelines
• Future trends and implications
• Chapter 1 Introduction
  • Summary
  • Introduction
  • Disease description
  • Type 1 diabetes
  • Type 2 diabetes
  • An increasing global health concern
  • Increasing patient population
  • Underdiagnosed and undertreated
  • Economic burden
• Chapter 2 Currently marketed innovatives
  • Summary
  • Introduction
  • Current growth drivers
  • Insulins
  • Leading marketed innovatives within insulin
  • Exubera
  • Oral anti-diabetics (OADs)
  • Leading marketed innovatives in OADs
  • Other diabetic drugs
  • Leading marketed innovatives in other diabetic drugs
• Chapter 3 Future drivers of growth and innovation
  • Summary
  • Introduction
  • Unmet need
  • Key events in the global diabetes market
  • ACCORD trial halted 18 months early
  • Inhaled insulins fail to impact market
  • FDA considers stricter rules for diabetes drugs
  • Toward the prevention and further treatment of diabetes
  • Non-invasive forms of insulin via new drug delivery technologies
  • Inhaled insulins
  • Future potential of inhaled insulins
  • Oral insulins
  • Future potential of oral insulins
  • Insulin patches
  • Future potential of insulin patches
  • Emerging new drug classes: targeting underlying causes
  • Incretin mimetics: GLP-1 agonists and DDP-IV inhibitors
  • GLP-1 agonists in development
  • Novel GLP-1 agonists addressing unmet need
  • DDP-IV inhibitors in development
  • Novel DDP-IV inhibitors addressing unmet need
  • PPAR agonists
  • PPAR agonists in development
  • Novel PPAR agonists addressing unmet need
  • Sodium glucose co-transporter (SGLT) inhibitors
  • SGLT inhibitors in development
  • Cannabinoid-1 (CB1) receptor antagonists
  • CB-1 receptor antagonists in development
  • Glucokinase activators (GKA)
  • Glucokinase activators in development
  • Other novel drugs in development
  • Protein tyrosine phosphatase 1B (PT1B) inhibitors
  • Glycogen synthase kinase-3 (GSK-3) inhibitors
  • 11-beta-hydroxysteroid dehydrogenase (11beta-HSD1) inhibitors
  • GPR119 agonists
  • Cell transplantation and innovative therapies
• Chapter 4 Key companies and pipelines
  • Summary
  • Introduction
  • Leading competitive strategies
  • Lifecycle management
  • Diversification
  • Franchise development
  • New market entry
  • Leading players
  • Novo Nordisk
  • Currently marketed innovatives profile
  • R&D/innovatives profile
  • Takeda
  • Currently marketed innovatives profile
  • R&D/innovatives profile
  • Sanofi-Aventis
  • Currently marketed innovatives profile
  • R&D/innovatives profile
  • GSK
  • Currently marketed innovatives profile
  • R&D/innovatives profile
  • Lilly
  • Currently marketed innovatives profile
  • R&D/innovatives profile
  • Merck
  • Currently marketed innovatives profile
  • R&D/innovatives profile
• Chapter 5 Future trends and implications
  • Summary
  • Introduction
  • Future market growth
  • Competitive strategy and future potential
• Chapter 6 Appendix
  • IMS data
  • Index
• List of Figures
  • Figure 3.1: Unmet needs in diabetes, 2008
  • Figure 3.2: Innovative diabetes pipeline, 2007
  • Figure 3.3: Addressing unmet need of novel GLP-1 agonists versus insulin
  • Figure 3.4: Addressing unmet need of novel DDP-IV inhibitors versus TZDs
  • Figure 3.5: Addressing unmet need of novel PPAR agonists* versus TZDs
  • Figure 4.6: Competitive dynamics of the leading players in the diabetes market, 2007
  • Figure 5.7: Drivers and resistors of growth in the innovative diabetes market, 2007
  • Figure 5.8: Forecast sales growth for the global diabetes market, 2007-12
  • Figure 5.9: Outlook for leading pharmaceutical companies in the innovative diabetes market
  • Table 2.1: Breakdown of the global diabetes market by drug class, 2003-07
  • Table 4.2: Leading diabetes companies*, 2006-07
  • Table 4.3: Novo Nordisk''s currently marketed innovative diabetes profile, 2003-07
  • Table 4.4: Novo Nordisk''s diabetes R&D/innovatives profile
  • Table 4.5: Takeda''s currently marketed innovative diabetes profile, 2003-07
  • Table 4.6: Takeda''s diabetes R&D/innovatives profile
  • Table 4.7: Sanofi-Aventis'' currently marketed innovative diabetes profile, 2003-07
  • Table 4.8: Sanofi-Aventis'' diabetes R&D/innovatives profile
  • Table 4.9: GSK''s currently marketed innovative diabetes profile, 2003-07
  • Table 4.10: GSK''s diabetes R&D/innovatives profile
  • Table 4.11: Lilly''s currently marketed diabetes innovative diabetes, 2003-07
  • Table 4.12: Lilly''s diabetes R&D/innovatives profile
  • Table 4.13: Merck''s currently marketed innovative diabetes profile, 2003-07
  • Table 4.14: Merck''s diabetes R&D/innovatives profile